The Effect of Thrombolytic, Anticoagulant, and Vasodilator Agents on the Survival of Random Pattern Skin Flap

Abstract

Background The aim of this study was to investigate the effect of subcutaneously applied thrombolytic, anticoagulant, and vasodilator agents on the survival of random-pattern skin flap.

Methods A caudally based dorsal flap model was used in 24 rats in four groups. In group 1 (n = 6), flap was elevated and sutured. In group 2 (n = 6), enoxaparin sodium was injected subcutaneously immediately after surgery, on days 1 and 2. In group 3 (n = 6), a transdermal nitroglycerin was applied directly following surgery, on days 1 and 2. In group 4 (n = 6), alteplase was injected subcutaneously immediately after surgery, on days 1 and 2. Blood flow was measured with laser Doppler flowmetry at the proximal and distal halves of flap before, immediately after surgery, and on days 3 and 7. Histologic samples were taken from the same locations on day 3 and day 7 postoperatively. Vessel and lymphocyte count was obtained. Photographs were taken to determine flap necrosis areas at day 7 postoperatively.

Results Area of skin necrosis was found to be less in all medication groups. But only enoxaparin sodium group showed significant decrease in skin necrosis (p < 0.05). Laser Doppler flowmetry showed a gradual decrease in all groups over time, with no statistically significant result. The histologic findings revealed the induction of angiogenesis in all experimental groups.

Conclusion Subcutaneously applied thrombolytic, anticoagulant, and vasodilator agents increase random-pattern skin flap survival with only enoxaparin sodium showing significant decrease in flap necrosis.

Keywords

anticoagulant - thrombolytic - skin flap - vasodilator

Note

This article was presented at the 33rd Annual Meeting of Turkish Society of Plastic and Reconstructive Surgery, 2011, in Izmir, Turkey.

• References

• 1 Grabb W. Basic Techniques of Plastic Surgery. Boston, MA: Little Brown; 1979: 36
• 2 Kerrigan CL, Daniel RK. Pharmacologic treatment of the failing skin flap. Plast Reconstr Surg 1982; 70 (5) 541-549
• 3 Donovan W. Experimental model in skin flap research. In: Grabb WC, Myers MB, , eds. The Skin Flaps. Boston, MA: Little Brown; 1975: 11-20
• 4 Rohrich RJ, Cherry GW, Spira M. Enhancement of skin-flap survival using nitroglycerin ointment. Plast Reconstr Surg 1984; 73 (6) 943-948
• 5 Coruh A, Abaci K, Gunay GK. Effect of topical nitroglycerine on the survival of ischemic flow-through venous flaps in rabbits. J Reconstr Microsurg 2004; 20 (3) 261-266
• 6 Xiao-Xiao T, Sen-Min W, Ding-Sheng L. Effects of vinpocetine on random skin flap survival in rats. J Reconstr Microsurg 2013; 29 (6) 393-398
• 7 Fang T, Lineaweaver WC, Chen MB, Kisner C, Zhang F. Effects of vascular endothelial growth factor on survival of surgical flaps: a review of experimental studies. J Reconstr Microsurg 2014; 30 (1) 1-13
• 8 Wang Y, Orbay H, Huang C , et al. Preclinical efficacy of slow-release bFGF in ischemia-reperfusion injury in a Dorsal Island skin flap model. J Reconstr Microsurg 2013; 29 (5) 341-346
• 9 Mathes SJ. Plastic Surgery. Vol. 1. Philadelphia, PA: Saunders; 2006
• 10 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337 (10) 688-698
• 11 Miyawaki T, Jackson IT, Elmazar H , et al. The effect of low-molecular-weight heparin in the survival of a rabbit congested skin flap. Plast Reconstr Surg 2002; 109 (6) 1994-1999
• 12 Chung TL, Holton III LH, Silverman RP. The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model. Ann Plast Surg 2006; 56 (3) 312-315
• 13 Eom JS, Koh KS, Al-Hilal TA , et al. Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats. Thromb Res 2010; 126 (3) e220-e224
• 14 Malm K, Dahlbäck B, Arnljots B. Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg 2003; 111 (5) 1659-1666
• 15 Iba T, Okamoto K, Ohike T , et al. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. J Trauma Acute Care Surg 2012; 72 (1) 177-182
• 16 Iba T, Aihara K, Watanabe S , et al. Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome. Cardiovasc Ther 2013; 31 (5) 280-284
• 17 Grosskopf I, Shaish A, Ray A, Harats D, Kamari Y. Low molecular weight heparin-induced increase in chylomicron-remnants clearance, is associated with decreased plasma TNF-α level and increased hepatic lipase activity. Thromb Res 2014; 133 (4) 688-692
• 18 Iba T, Miyasho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 2008; 12 (4) R86
• 19 Caça I, Sahin A, Cingü AK, Ari S, Alakuş F, Cinar Y. Effect of low molecular weight heparin (enoxaparin) on congenital cataract surgery. Int J Ophthalmol 2012; 5 (5) 596-599
• 20 Hashimoto I, Nakanishi H, Shono Y, Yamano M, Toda M. The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1. Plast Reconstr Surg 2003; 111 (7) 2307-2314
• 21 Ayhan S, Uygur S, Kucukoduk I, Sencan A. Salvage of a congested DIEAP flap with subcutaneous recombinant tissue plasminogen activator treatment. J Plast Reconstr Aesthet Surg 2009; 62 (11) e453-e454
• 22 Tran NV, Buchel EW, Convery PA. Microvascular complications of DIEP flaps. Plast Reconstr Surg 2007; 119 (5) 1397-1405 , discussion 1406–1408
• 23 Jones BM. Monitors for the cutaneous microcirculation. Plast Reconstr Surg 1984; 73 (5) 843-850
• 24 Smit JM, Zeebregts CJ, Acosta R, Werker PM. Advancements in free flap monitoring in the last decade: a critical review. Plast Reconstr Surg 2010; 125 (1) 177-185
• 25 Roche Gamón E, De la Cuadra Oyanguren J, Pérez Ferriols A, Fortea Baixauli JM. Contact dermatitis from nitroglycerin in a transdermal therapeutic system. Acta Derm Venereol 2006; 86 (6) 544-545
• 26 Pérez-Calderón R, Gonzalo-Garijo MA, Rodríguez-Nevado I. Generalized allergic contact dermatitis from nitroglycerin in a transdermal therapeutic system. Contact Dermat 2002; 46 (5) 303